Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice

T. Nagai, Y. Noda, T. Une, K. Furukawa, H. Furukawa, Q. M. Kan, T. Nabeshima

研究成果: Article

49 引用 (Scopus)

抜粋

The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

元の言語English
ページ(範囲)269-272
ページ数4
ジャーナルNeuroReport
14
発行部数2
DOI
出版物ステータスPublished - 10-02-2003
外部発表Yes

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

これを引用

Nagai, T., Noda, Y., Une, T., Furukawa, K., Furukawa, H., Kan, Q. M., & Nabeshima, T. (2003). Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice. NeuroReport, 14(2), 269-272. https://doi.org/10.1097/00001756-200302100-00023